(0.54%) 5 073.50 points
(0.30%) 38 183 points
(0.75%) 17 568 points
(1.00%) $79.79
(2.43%) $1.979
(0.14%) $2 314.20
(-0.27%) $26.68
(0.71%) $961.70
(0.13%) $0.934
(0.42%) $11.08
(0.06%) $0.799
(-1.47%) $91.89
Live Chart Being Loaded With Signals
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids...
Stats | |
---|---|
今日成交量 | 47 802.00 |
平均成交量 | 11 877.00 |
市值 | 14.44M |
EPS | $0 ( 2024-04-03 ) |
下一个收益日期 | ( $-0.120 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.540 |
ATR14 | $0.0580 (0.50%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-06-21 | Barbier Ann | Buy | 40 000 | Stock Option (right to buy) |
2023-06-21 | Geraghty James A | Buy | 45 000 | Stock Option (right to buy) |
2023-06-21 | Kiener Peter A | Buy | 40 000 | Stock Option (right to buy) |
2023-06-21 | Kiritsy Christopher P | Buy | 40 000 | Stock Option (right to buy) |
2023-06-21 | Richman Michael | Buy | 40 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
16.91 |
Last 97 transactions |
Buy: 6 636 987 | Sell: 4 508 050 |
音量 相关性
Pieris Pharmaceuticals 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Pieris Pharmaceuticals 相关性 - 货币/商品
Pieris Pharmaceuticals 财务报表
Annual | 2023 |
营收: | $42.81M |
毛利润: | $41.03M (95.84 %) |
EPS: | $-21.80 |
FY | 2023 |
营收: | $42.81M |
毛利润: | $41.03M (95.84 %) |
EPS: | $-21.80 |
FY | 2022 |
营收: | $25.90M |
毛利润: | $23.12M (89.27 %) |
EPS: | $-0.420 |
FY | 2021 |
营收: | $31.42M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.675 |
Financial Reports:
No articles found.
Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。